GIA
IOVA icon

Gladstone Institutional Advisory’s Iovance Biotherapeutics IOVA Stock Holding History

Gladstone Institutional Advisory’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-17,223
Closed -$473K – 285
2020
Q2 		$473K Buy
+17,223
New +$566K 0.12% 135

Other funds holding IOVA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return

Gladstone Institutional Advisory's IOVA Position: Q3 2020 in Review

Gladstone Institutional Advisory sold out of Iovance Biotherapeutics (IOVA) in Q3 2020, closing a stake of 17,223 shares — an estimated $473K sold.

Gladstone Institutional Advisory first reported a position in IOVA in Q2 2020 and held it in 1 quarter. The position peaked at $473K in Q2 2020. 252 funds tracked by Wall St. Rank hold IOVA as of Q3 2020.

  • Gladstone Institutional Advisory reported no remaining Iovance Biotherapeutics position as of Q3 2020 after selling out during the quarter.
  • Gladstone Institutional Advisory sold 17,223 Iovance Biotherapeutics shares in Q3 2020, an estimated $473K.
  • Gladstone Institutional Advisory first reported a position in Iovance Biotherapeutics in Q2 2020 and held it in 1 quarter.
  • Gladstone Institutional Advisory's Iovance Biotherapeutics position peaked at $473K in Q2 2020.
  • 252 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q3 2020.

Based on Gladstone Institutional Advisory's 13F filing for Q3 2020, filed 16 Nov 2020.